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Background: Optimising filter life and performance efficiency in continuous renal replacement therapy has been a
focus of considerable recent research. Larger high quality studies have predominantly focussed on optimal
anticoagulation however CRRT is complex and filter life is also affected by vascular access, circuit and management
factors. We performed a systematic search of the literature to identify and quantify the effect of vascular access,
circuit and patient factors that affect filter life and presented the results as a meta-analysis.
Methods: A systematic review and meta-analysis was performed by searching Pubmed (MEDLINE) and Ovid
EMBASE libraries from inception to 29th February 2016 for all studies with a comparator or independent variable
relating to CRRT circuits and reporting filter life. Included studies documented filter life in hours with a comparator
other than anti-coagulation intervention. All studies comparing anticoagulation interventions were searched for
regression or hazard models pertaining to other sources of variation in filter life.
Results: Eight hundred nineteen abstracts were identified of which 364 were selected for full text analysis. 24
presented data on patient modifiers of circuit life, 14 on vascular access modifiers and 34 on circuit related factors.
Risk of bias was high and findings are hypothesis generating.
Ranking of vascular access site by filter longevity favours: tunnelled semi-permanent catheters, femoral, internal
jugular and subclavian last. There is inconsistency in the difference reported between femoral and jugular catheters.
Amongst published literature, modality of CRRT consistently favoured continuous veno-venous haemodiafiltration
(CVVHD-F) with an associated 44% lower failure rate compared to CVVH. There was a trend favouring higher blood
flow rates. There is insufficient data to determine advantages of haemofilter membranes.
Patient factors associated with a statistically significant worsening of filter life included mechanical ventilation,
elevated SOFA or LOD score, elevations in ionized calcium, elevated platelet count, red cell transfusion, platelet
factor 4 (PF-4) antibodies, and elevated fibrinogen.
Majority of studies are observational or report circuit factors in sub-analysis. Risk of bias is high and findings require
targeted investigations to confirm.
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Conclusion: The interaction of patient, pathology, anticoagulation, vascular access, circuit and staff factors
contribute to CRRT filter life. There remains an ambiguity from published data as to which site and side should be
the first choice for vascular access placement and what interaction this has with patient factors and timing. Early
consideration of tunnelled semi-permanent access may provide optimal filter life if longer periods of CRRT are
anticipated. There remains an absence of robust evidence outside of anti-coagulation strategies despite over
20 years of therapy delivery however trends favour CVVHD-F over CVVH.
Keywords: Continuous renal replacement therapy, CRRT, Vascular access, Filter life, Femoral, Jugular, Vein
Background
Continuous renal replacement therapy (CRRT) is a com-
mon intervention to maintain physiologic plasma com-
position when acute kidney injury (AKI) complicates
critical illness. CRRT by definition relies on continuous
blood flow through the extra-corporeal circuit to sup-
port controlled clearance of solutes and water balance.
Failures of the extracorporeal circuit interrupt treatment
delivery, increase cost and are potentially disruptive to
other aspects of patient care.
Optimising filter life and performance efficiency in
CRRT has been a focus of considerable recent research.
Larger high quality studies have predominantly focussed
on optimal anticoagulation strategies and this has
formed the core of several reviews [1–6] with a recent
meta-analysis [6, 7] favouring citrate over regional
heparin to extend filter life.
Though narrative reviews exist focussing on non-
anticoagulant parameters that affect filter life [1–3], no
meta-analysis has ever pooled published data in this area.
We performed a systematic search of the literature to
identify and quantify the effect of non-anticoagulant
factors and interventions that influence filter life in con-
tinuous renal replacement therapy. We have arbitrarily
divided non-anticoagulant determinants of filter life into
vascular access factors, circuit factors and patient factors.
Adequate vascular access allows the desired blood flow
to be achieved without generating extremes of pressure
between the extracorporeal circuit and the patient. Poor
access results in frequent CRRT platform alarms and
failure of treatment delivery or reductions in blood flow
that may decrease therapy effectiveness and promote
stasis with subsequent thrombosis [1–3]. Obtaining
vascular access for CRRT is a frequently performed
procedure. Veno-venous (VV) techniques have largely
supplanted arterio-venous (AV) cannulation due to the
availability and relative ease of wire-guided dual lumen
catheters. However many possible combinations of vas-
cular access catheter design, size, insertion site, inserter
experience, depth of insertion and line maintenance
make determining the optimal combination complex.
Patient factors such as body habitus, pathology and co-
agulopathy all contribute to the ease of performing CRRT
and maintaining vascular access. Circuit factors include
the modality of treatment with continuous veno-venous
haemodialysis (CVVHD), haemofiltration (CVVH), and
haemodiafiltration (CVVHD-F) all in common usage.
Variation in practice also encompasses use of pre/post
dilution in CVVH and CVVHD-F, target blood and fluid
flow rates and circuit management practices.
Methods
Databases of reviews were searched for similar meta-
analyses and none were found. A preliminary literature
search identified that the majority of studies were obser-
vational in nature being either primary observation stud-
ies or contained as sub-analyses of randomised studies.
Given that our goal was to identify factors and interven-
tions and develop hypotheses for future studies, inclu-
sion of observational evidence was deemed acceptable.
Consequently a systematic review strategy was devel-
oped following the MOOSE guideline statement for
Meta-Analyses and Systematic Reviews of Observational
Studies [8].
Search strategy
The search strategy was developed by an experienced
researcher (MB) and assistance provided by library staff.
We searched Pubmed (MEDLINE) and Ovid EMBASE
libraries to 29th February 2016 with no restrictions utilis-
ing keywords, variant spellings and wildcards (Table 1).
Manual review of references from included studies and
potentially relevant related citations was also performed.
Included studies
All abstracts were imported into Zotero (version
4.0.28.8, George Mason University, Fairfax, VA, USA)
and duplicate entries from different databases merged.
Abstracts were screened independently by two re-
searchers (MB, EW) for potential relevance after which
full text versions of the papers were obtained for all
potentially relevant studies.
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Studies were included if they documented filter life in
hours with a comparator other than anti-coagulation
intervention. All studies comparing anticoagulation in-
terventions were searched for regression or hazard
models pertaining to other variation in filter life.
Abstracts detailing proceeds of meetings and conference
abstracts were merged with studies by the same authors
if the results were clearly duplicate entries and otherwise
included. Foreign language articles were converted to
English using Google Translate [9].
Excluded studies
The following studies were excluded: Abstracts of phar-
macokinetic CRRT studies, studies on cytokine media-
tors, micronutrients or renal recovery as well as reviews
and prior meta-analyses.
We also excluded studies that solely documented filter
life in a population without any comparators or relation-
ship to independent variables, studies describing arbi-
trary levels of filter life without a baseline group (e.g.
arbitrarily comparing survival curves between ‘short’ and
‘long’ filter life) and results that divided filter life into
dichotomous time periods without specifying hours per
filter or similar variations such as numbers of filters per
day. In these cases authors were contacted regarding
obtaining original data. Bench studies or studies involv-
ing animals were also excluded.
Data extraction & statistical methods
Filter life and basic study data were extracted directly into
Comprehensive Meta-Analysis version 3.3.070 [10] while
study details were entered directly into Revman version
5.3 [11] after exporting citations from Zotero. Multiple re-
gression covariates (using the full model where available)
were converted to correlations using Rosenthal & Rubin’s
r-equivalent method [12–14]; when comparison of means
were also available we found this technique produced
similar effect size estimates. If survival curves were pre-
sented without hazard ratios, these were extracted using
methods detailed by Liu & Hanley [15–18] utilising
Engauge Digitizer version 6.2 [19] and R version 3.0.2 with
package survival [20, 21]. As a last resort medians and
interquartile ranges were converted to means using recog-
nised procedures and results requested from the study
author [22]. One author [23] provided original data for
which a survival analysis was performed in R version 3.0.2
with package survival version 2.38-3 [21] utilising a Cox
proportional hazards model and further pooled with the
authors (MB) previously published data [24] to produce
Kaplan Meier figures.
Comprehensive Meta-Analysis version 3.3.070 [10]
was utilised to present varying effect size estimates as
Odds Ratios (for risk of event data) or Hazard Ratios
(for time to event data) depending on the source. A ran-
dom effects model was used to combine similar variables
for summary effect estimates. Where a sub-group has
both Hazard and Odds Ratio effect size estimates, the
estimates are discussed in the text.
Quality and risk of bias was assessed utilising the
GRADE approach [25] as implemented in Revman ver-
sion 5.3 [11] and a summary of findings table created
using GRADEpro [25]. Heterogeneity was considered on
pragmatic grounds from sources of variability in the
study description and statistically when sufficient com-
parisons were present with an I2 statistic <50% denoting
low heterogeneity and >80% denoting high. We graded
risk of detection bias for observational studies according
to the trial design with a lower risk attributed to large
data sets reporting multiple factors and higher risk at-
tributed to retrospective analysis of an intervention or
cohort difference.
Classification of studies
The primary outcome was filter life. Factors associated
with filter life were arbitrarily divided into patient
factors, vascular access factors and circuit factors with
subgroups within each level. Studies reporting multiple
variables were included in more than one category.
Table 1 Search Strategy
Title and Abstract Search Title and Abstract Search/MeSH Terms
CRRT OR continuous renal replacement therapy OR CVVHD-F
OR CVVD OR CVVH OR CVVHD
OR continuous venovenous OR continuous veno-venous OR continuous veno
venous
AND haemodiafiltration OR haemodiafiltration OR hemofiltration OR
haemofiltration OR ultrafiltration
AND
extracorporeal circulation OR circuit* OR filter* OR vascular access
OR access catheter OR catheter OR securement OR flush OR lock*
OR haemofilter or haemofilter or blood flow or ultrasound OR vein
AND safety events OR bleeding dislodgement or disconnect* OR recirculat*
OR dysfunction OR failure OR life* OR interruption OR survival OR
thrombosis OR clot* OR coagulant* OR “blood coagulation” [MeSH Terms]
OR clearance OR flux OR homeostasis OR acid base OR strong ion difference
OR effectiveness OR efficacy or biocompatibility OR body habitus OR
obesity OR patient position OR physiotherapy OR physical therapy OR
mobilisation OR education OR training OR experience
* = wildcard search character
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Results
Search results (Fig. 1)
A total of 819 abstracts were identified of which 364
were selected for full text analysis. The study selection
process is outlined in Fig. 1. Characteristics of included
studies are displayed in Tables 2, 3 and 4 . The most
common reason for study exclusion was failure to de-
scribe filter life in hours. Figure 2 describes the overall
bias summary of included studies. Bias summaries for
individual studies are included with the forest plots. The
authors of three studies provided clarifying information
upon request and one author provided original data for
reanalysis [23].
Fourteen studies contain filter life data related to
vascular access properties. None of these were of
high quality. Only one had a randomised design
where the primary outcome was filter life [26], while
a second randomised trial presented a post-hoc ana-
lysis of filter life by vascular access site [27]; neither
was blinded. Two high quality randomised trials
were identified in the literature search that did not
report filter life related to vascular access but to
catheter function; these are discussed in the relevant
sections [28, 29].
Thirty-four studies contain filter life data related to
circuit factors of which 13 had a prospective randomised
design but only two were blinded. Twenty-four studies
contain filter life data related to patient variables how-
ever the majority of indices of filter life were from sub-
analyses. No large high quality randomised studies
existed. Only five studies in this analysis had a prospect-
ive randomised design [30–34] and of these only one
described blinding of investigators.
Overall filter life
Amongst included studies from the entire systematic
review where mean filter life was available, overall
mean filter life was 21.92 h (n = 7502, SD = 10.89).
Fig. 1 Article flow through systematic review process
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Vascular access factors and filter life
Access site and filter life
Figure 3 displays grouped effect estimates for comparisons
between vascular access sites. The femoral vein was the
most common vascular access site utilised across studies
that contained filter life data. Significant dispersion of
estimates exists between studies comparing femoral and
non-femoral access routes. No data existed on the order
of catheter insertion sites in individual patients.
Of studies reporting internal jugular vs. femoral cath-
eter sites, du Cheyron [35] in 78 patients favoured in-
ternal jugular access whereas the grouped effect estimate
of studies reporting time to event outcomes trended
toward the femoral site with an associated 27% (95% CI
−4% to 69%, p = 0.092) increase in filter survival with
low heterogeneity (I2 = 24.8%).
Results comparing subclavian vs femoral catheters also
suggested a trend associating improved filter life from
femoral access whereas tunnelled semi-permanent cath-
eters and direct connection to ECMO circuits were asso-
ciated with longer filter life when compared to femoral
access. Again statistical significance was influenced by
choice of statistical model for the pooled effect with
fixed effects models reaching significance.
Datasets made available from two studies [23, 24] were
pooled to construct survival curves by filter site for 2173
filters. Subclavian access was associated with signifi-
cantly worse filter life than femoral access whereas tem-
porary internal jugular catheters was no different.
Tunnelled access (14.5Fr) trended toward longer filter
life while a direct connection to ECMO provided the
longest filter life (Fig. 4).
Though not reporting filter life, an important sub-
analysis of a large multi-centre study of CRRT dose [29]
suggested femoral catheters had limited impact on
CRRT dose delivery compared to non-femoral catheters.
A single small study described patient activity and
catheter site with filter life; Wang et al. [36] found at
baseline non-femoral catheters were associated with lon-
ger filter life however this advantage did not persist with
mobilisation.
Access side and filter life (Fig. 5)
Three studies provided comparison data on the side of
vascular access. Results for femoral side were heteroge-
neous (I2 = 82.8%) with the study by Kim [37] a signifi-
cant outlier.
Of relevance to side selection is a multicentre rando-
mised control trial that investigated time to catheter
dysfunction as an outcome rather than filter life [28]
between right or left jugular and femoral placement in
intermittent haemodialysis and/or CRRT. This study
found no significant difference in risk of dysfunction be-
tween right jugular and femoral sites (trend favoured
right jugular) however left jugular performed signifi-
cantly worse (adjusted hazard ratio vs femoral 1.89 (95%
CI 1.12 – 3.21, p < 0.02)).
Catheter properties associated with filter life (Fig. 6)
A single randomised comparison of catheter length [38]
in great thoracic veins with confirmation of atrial tip
placement vs superior vena cava tip positioning demon-
strated superiority of longer (atrial) catheters. Importantly
this study reported no difference in incidence of atrial or
ventricular arrhythmias between the two catheter lengths.
Only one study in a paediatric population reported
catheter size comparisons in relation to filter life [26]
demonstrating only a weak signal. However the effect is
likely greater given the report of a sub-analysis of the
large RENAL dataset [29] demonstrating achievement of
increased renal dose with larger catheters.
Extremely negative access pressures were associated
with decreased filter life [39] in a single study.
Catheter types association with filter life
All studies reporting differences between temporary vas-
cular access devices used a before-after design in an in-
tensive care unit. Across all studies a trend favouring the
Niagara catheter (Bard Canada) being associated with
longer filter life was observed however the pooled effect
was not significant. Tunnelled cuffed semi-permanent
devices trended towards superior filter life compared to
temporary devices in each analysis (Figs. 3, 4, and 7)
Fig. 2 Risk of Bias Graph. For non - randomised studies detection bias risk was graded by likely influence on findings
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– often these catheters have larger diameters (14.5Fr
to 15.5Fr).
Circuit factors associated with filter life
Haemofilter membrane characteristics (Fig. 8)
Studies comparing haemofilter membranes spanned
several advancements in membrane technology over a
22-year period. One early randomised study [40] demon-
strated an advantage of hollow fibre membranes over flat
plate haemofilter configurations for filter life while the
remainder analysed contemporary hollow fibre membranes.
Numbers of studies for each membrane comparison were
small.
A trend favouring polysulfone membranes ahead of
cellulose triacetate in being associated with longer filter
life was apparent in one multiple regression analysis [41]
but a newer modified cellulose membrane showed no
difference [42]. No significant difference in filter life
existed between the non-surface coated AN69 mem-
brane and a polysulfone membrane in one study [38].
Interestingly newer surface treated (heparin binding and
potentially more biocompatible) AN69ST membrane did
not show any advantage in filter life over the non-surface
treated AN69 in two randomised studies [43, 44].
Classically diffusive transport improves with haemofilter
membrane area and anecdotally increased membrane area
Fig. 3 Vascular access insertion site association with filter life. Effect estimates are grouped by category. Studies reporting as difference in means,
correlations or risk are summarised in odds ratios. Hazard ratios are presented separately
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prolongs filter life however a single study comparing
membrane area did not demonstrate an advantage [45].
CRRT mode, Pre vs post dilution and CRRT dose (Fig. 9)
The optimum modality of CRRT for filter life was con-
sistent across nearly all studies including two rando-
mised [46, 47] trials with CVVHD-F (or CVVHD [47])
associated with a 44% lower failure rate compared to
CVVH (Fig. 9). Statistical heterogeneity was low (I2 for
event risk comparisons 25.5%, p = 0.058; hazard ratio
comparisons zero) and the result reached significance in
time to event analysis (p < 0.001) with minimal dispersion.
Whether CVVH with pre or post dilution is superior
was less clear with more heterogeneity (I2 = 48.6%)
across risk results and no overall trend (p = 0.245). Of
the two small randomised studies in this group [48, 49]
only van der Voort et al. purely compared pre vs post di-
lution and favoured pre-dilution to prolong filter life.
Higher CRRT dosage, prescribed ultra-filtration rate
and fluid removal rate were not associated with differ-
ences in filter life amongst the retrospective analyses
that reported this outcome [36, 41, 50]. Although not
directly reporting filter life, the results of two large
multi-centre trials of RRT intensity are relevant in
regards to CRRT dose suggesting that higher intensity
RRT may be associated with decreased filter life; the
RENAL Investigators [51] used 0.93 ± 0.86 filters per day
in the high intensity group vs 0.84 ± 0.81 in the lower
group (p < 0.001). Similarly Palevsky et al. [52] report
3178 CRRT treatments in 563 patients in the intensive
arm vs 2789 in 561 patients in the lower intensity group.
Blood flow and filter life (Fig. 10)
Higher blood flow rates have been hypothesised to
prolong filter life by minimising stasis within the blood
path [3] however results vary across studies. Of the three
studies with randomised design none detected a differ-
ence though blood flow was not the primary outcome in
the comparison by Choi et al. [30] and the studies by
Ramesh Prasad et al. [53] and de Pont et al. [48] did not
solely assess blood flow.
Though Mottes [38] did not show a significant associ-
ation between blood flow and filter life, the pooled effect
of studies contributing to the hazards model favoured
higher blood flow (HR = 0.942, p = 0.009, I2 = 25.8%).
This equates to a 5.8% increase in filter survival for each
10 ml/min increase in blood flow however as none of
Fig. 4 Pooled survival analysis of filter life by vascular access site
from 2173 filters from two studies [23, 24]. * signifies curves that
demonstrate a statistically significant difference to femoral
access. Sites denote temporay catheters except for tunnelled
semi - permanent devices and ECMO
Fig. 5 Access side and Filter Life. HR denotes original study data was re - analysed for meta - analysis with a Cox proportional hazards model
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these studies were designed to directly compare low and
high blood flow, this result should be considered sup-
portive only.
The single study [54] investigating a gradual step up of
initial blood pump speed to 200 ml/min over a shorter
4 min period vs a 10 min period found no benefit on
patient haemodynamic parameters and a trend toward
worse filter life at the slower step up.
Blood path interventions associated with Filter Life
Two small studies showed no benefit from different sites
of heparin delivery [55, 56]. No benefit was observed
using a modified horizontal bubble trap on the return
line [57], priming the circuit with albumin before use
[58] to improve biocompatibility or by the presence or
absence of a fluid warmer on the return blood path [59].
Saline flushing of the circuit was not beneficial
however the only randomised study [53] simultaneously
compared differences of blood flow. The remaining stud-
ies [60–63] utilised saline flushes in patients with a coagu-
lopathy that contra-indicated use of heparin.
CRRT system management and staff education
interventions (Fig. 11)
The number of alarms and an arbitrary definition of
CRRT mechanical failure were both associated with
worse filter life in two small studies [36, 63]. Educa-
tion around overall CRRT management with a struc-
tured simulation event was beneficial in two studies
though only the study by Mottes et al. [38] purely
assessed focussed education alone without other
interventions.
Fig. 6 Catheter Properties associated with filter life
Fig. 7 Catheter type. Arrowgard Blue denotes a group comprising 16 cm or 20 cm 12Fr or 25 cm 14Fr polyurethane antimicrobial treated
catheters. Niagara when not specified denotes a group comprising 15 cm, 20 cm or 24 cm 13.5Fr polyurethane catheters. HR denotes reanalysis
of the original data by Cox proportional hazards model
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Patient factors associated with filter life
Patient factors
Figure 12 presents grouped effect size estimates for
patient factors associated with CRRT filter life. Among
baseline factors increasing patient age and blood pres-
sure were not associated with a difference in filter life
however male sex trended toward shorter filter life
with the pooled hazard estimate nearly reaching stat-
istical significance though heterogeneity was moderate
(p = 0.065, I2 = 54.4%).
Increases in body temperature demonstrated a non-
significant signal toward association with shorter filter
life in one study with a 14.9% (95% C.I. −1.7% to
34.4%) increase in the failure rate per degree Celsius
elevation [64]. Another single study suggested that
presence of mechanical ventilation was associated
with worse filter life while vaso-active drug therapy
was an advantage [50].
Patient pathology (Fig. 12)
The most common pathology reported was sepsis. In
general studies reported sepsis to have a negative
effect on filter life with Ghitescuet [65] suggesting
septic shock and sepsis fall on a continuum to reduce
filter life further however the effect did not reach
significance.
Filter life in the setting of liver failure with bilirubin >
3 mg/dL nearly reached significance for being associated
with worse filter life. Not included in the forest plot due
to the number of contrasts and no attempt to control
for other variables is a study by Agarwal et al. [66] which
contrasted anticoagulation free filter life in coagulo-
pathic patients with acute liver failure, decompensated
chronic liver disease, post liver transplant recipients,
sepsis or haematological disorders. They found that
haematological disorders had significantly longer filter
life (x̄=21.7 ± 19.7 h) however all other groups demon-
strated poor filter life with mean duration less than 12 h.
The most comprehensive description of patient factors
interacting with filter life in acute liver failure or decom-
pensated liver disease is found in Chua et al. [50] where
MELD score, APTT, bilirubin, mechanical ventilation,
platelet count and INR were associated with filter life in
this population. Discussions regarding filter life and
anti-coagulation in liver failure patients requiring CRRT
are the subject of several studies [50, 66–71] and grow-
ing support is emerging for the safety and efficacy of
citrate in this population [70].
Illness severity (Fig. 12)
Illness severity scoring systems demonstrated heteroge-
neous association with filter life effect. The summary
effect for increasing APACHE II and III (I2 = 57.2%)
scores demonstrated no association with filter life how-
ever higher SOFA scores and higher LOD scores were
associated with decreased filter life in isolated studies.
Biochemical parameters (Fig. 13)
Only two studies displayed sub-analyses of biochem-
ical abnormalities in association with filter life [41, 64].
A single study suggested lactate concentration displayed
an association between high lactate and shorter filter life
with a 14% (95% C.I. 3%–23%) increase in failure rate
per 1 mmol/L increase in lactate.
Two studies suggested higher ionised calcium was
associated with shorter filter life (neither study was using
Fig. 8 Grouped effect estimates of haemofilter membrane characteristics associated with filter life
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citrate anticoagulation) however the effect direction was
not consistent.
Lower pH was associated with longer filter life equat-
ing to a 59% (95% C.I. 10% to 59%) increase in filter sur-
vival rate per 0.1unit fall in pH. Zhang et al. [64] also
demonstrated statistical significance between Kaplan-
Meier curves for pH above or below 7.35 however inter-
actions between pH and other patient factors are not
explored.
Blood parameters (Fig. 13)
Blood count parameters demonstrated no significant
association between haemoglobin (or haematocrit) mea-
surements and filter life. There was inconsistency between
higher platelet counts and shorter filter life; amongst re-
sults reported as odds ratios the summary effect for higher
platelet counts reached statistical significance though het-
erogeneity was moderate (p < 0.0005, I2 = 53.5%) whereas
the result for studies reporting a hazard ratio was not sig-
nificant. A single study suggested higher neutrophil
counts were associated with decreased filter life [41].
Receipt of a platelet or packed red cell infusion were
both associated with a reduction in filter life though plate-
let infusion did not quite reach statistical significance.
Coagulation parameters (Fig. 14)
A positive association between APTT and filter life
was observable amongst studies reporting as odds ratio
Fig. 9 Grouped estimated effect sizes for CRRT Modes, Pre vs Post Dilution CVVH and CRRT Fluid Dosing in relation to filter life
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studies (p = 0.034) with a 1 s increment increasing the
odds of filter survival by 1.17. However an inconsist-
ent trend toward shorter filter life reached significance
for pooled hazard ratios though clinically insubstantial
(odds of failure increase by 1.004 for each second in-
crease). Heterogeneity for APTT was moderately high
I2 = 75.9%. INR and prothrombin time (PT) subgroups
were inconsistent in effect direction. Utilising eleva-
tions in prothrombin fragment F1 + 2 to measure anti-
coagulation had a positive association with increased
filter life [72].
Fresh Frozen Plasma (FFP) administration was associ-
ated with a non-significant increase in the failure rate
however this was only reported in one study [53].
Of interest were studies [32, 33, 35, 67, 73] reporting
heparin resistance from low anti-thrombin III levels
(AT-III). Higher AT-III levels trended to longer filter life,
reaching significance in one study [33] while correction
of AT-III deficiency was associated with a pooled 18.8%
increase in filter life.
The presence of platelet-factor 4 antibodies (PF4)
against heparin was significant in one study [74] which
Fig. 10 Grouped estimated effect sizes of blood flow and blood pathway interventions associated with filter life. HR denotes the re - analysis of
Dunn and Sriram, 2014 [23] using a Cox proportional hazards model. Qb denotes blood flow
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went on to demonstrate filter life comparable to non-
PF4 positive patients after switching from heparin to
danaparoid.
Higher fibrinogen levels were inconsistent in associ-
ation with filter life with no effect reported by Stefanidis
et al. [73] however a 50.8% increase in the failure rate
for each 1 g/L increase in fibrinogen reported by Fu et al.
[41] (p < 0.005).
Mobilisation and position (Fig. 14)
A single study by Wang et al. [36] challenged the widely
held belief that CRRT should be stopped for physiother-
apy however the small numbers and trial design is open
to observation bias. Another recent study by Toonstra
et al. [75] affirmed that patient safety with CRRT and
mobilisation can be maintained with care.
Kim et al. [37] explored the fraction of time patients
spent in various positions with femoral vascular access
and did not show a favoured side however that the
supine position was used in nearly 50% of observations.
Unfortunately, they did not report the interaction
between position and left or right femoral catheters.
Discussion
This systematic review identified all published studies
presenting comparisons of non- anticoagulant factors in
relation to filter life. Overall filter life amongst included
studies was less than 24 h with wide variation and well
short of the multiple days that many filters can last. An
interpretative summary of findings is presented in
Table 5.
Vascular access
Insertion of vascular access devices for CRRT is a
very common occurrence however data to guide opti-
mal catheter site is not strong. The heterogeneity in
filter life between femoral and internal jugular siting
suggest that unstudied factors such as timing of de-
vice in relation to severity of illness, patient factors
(such as siting the device in a femoral location for
sedation patients or upper body for upright patients)
and operator experience may be important. Studies
using time to catheter dysfunction [28, 76] as the out-
come have similarly mixed results though the only
randomised study found no difference [28] between
femoral and jugular. Further analysis of large datasets
may provide clarity – in particular studies are
required that report the order of catheters.
Of interest was the result from Wang et al. [36] that
patient mobilisation was not associated with any differ-
ence in filter life between femoral and non-femoral
catheter sites. CRRT practice has typically minimised
patient mobilisation but it could be safe and feasible
without therapy interruption [36, 75]. More studies are
needed to guide optimal siting of devices in recovering
patients in order to allow ambulation while undergoing
CRRT.
The randomised study by Morgan [26] demonstrating
superiority of atrial over superior vena cava placement
may suggest that studies where the femoral site was
found superior could have found less difference if thor-
acic catheter location had been accounted for. Similarly,
the advantage of tunnelled devices may result from the
more frequent use of live x-ray positioning to ensure
optimal placement during insertion as opposed to only
follow up x-rays for tip placement for placement within
intensive care units.
Offsetting any advantage to filter life of femoral or
jugular catheter placement over subclavian access is the
possibility of a lower infection risk at subclavian sites
[77–79]. However subclavian access is associated with
an increased risk of strictures with one study reporting
this event in 50% of subclavian veins from short term tem-
porary dialysis catheter placement [80]. Our conclusion is
Fig. 11 Grouped effect estimates of system management factors and education interventions associated with filter life
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Fig. 12 Baseline patient data, pathology and illness severity associations with CRRT filter life. Effect estimates are grouped by category. Studies
reporting as difference in means, correlations or risk are summarised in odds ratios. Hazard ratios are presented separately
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Fig. 13 Biochemistry and blood parameters associated with CRRT filter life
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Fig. 14 Coagulation and Position/Mobilisation parameters associated with CRRT filter life
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Table 5 Summary of findings table
Outcomes Impact № of participants
(studies)
Quality of the evidence
(GRADE)
Vascular Access interventions to prolong filter life in CRRT
Temporary Vascular Access Site Optimal vascular access site ranked by association with
longer filter life is: tunneled semi-permanent, femoral or




Catheters vs Temporary Catheters
Tunneled semi-permanent vascular access devices were
consistently associated with longer filter life. A significant
confounder is that these devices were often larger internal
diameter than temporary devices however on the basis of
current literature they should be considered in any cases
expected to have prolonged CRRT requirement
(4 observational studies)
LOW b,c
Side of Vascular Access Catheter Overall there is insufficient data and possibility of significant
confounding by order of catheter choice such that optimal
side of vascular access cannot be determined
(3 observational studies)
LOW a
Catheter length at thoracic vein
sites
Favours longer catheter length with atrial placement when
thoracic veins utilised. Single study only however unlike most
filter life studies this was randomized. No increased in
arrhythmias with longer catheter length however
underpowered to detect complications.
(1 RCT)
MODERATE d
Catheter lumen size Only one small study directly measured filter life with
catheter size however indirect measures
(increased renal dose) in RENAL study supports catheter size
as important. Possible benefit from tunneled access may
be due to catheter size
(3 observational studies)
VERY LOW a,c,e
Number of vascular access related
alarms
Number of vascular access alarms is likely a significant
contributor to poor filter life however data is limited
(1 observational study)
VERY LOW g
Access Catheter Type No significant difference between brands of catheters




Circuit Management Interventions to Prolong Filter Life in CRRT
Haemofilter Membrane
Characteristics
Hollow fibre membranes appear superior to flat plate
membranes. It is unclear if an advantage exists for
polyacrylonitrile membranes compared to polysulfone or
cellulose membranes in regards to filter life. Membrane area
was not associated with increased filter life in a single study.
(8 observational studies)
VERY LOW h
CRRT Modality CVVH is associated with worse filter life in published studies (7 observational studies)
LOW i
Pre vs Post Dilution in CVVH One small RCT favoured pre-dilution. Overall affect from all




Blood Flow Rate Majority of trials suggest a higher blood flow rate increases
filter life however it is unclear over what range this applies.




Saline Flushes to Blood Path There is no evidence to support intermittent saline flushing





Limited evidence suggests focused training to recognise
and respond to filter warnings prolongs filter life
(4 observational studies)
VERY LOW i
Patient Factors associated with prolong filter life in CRRT
Factors with a positive association
with filter life
Increasing age (NS), Presence of vaso-active drugs (NS) f,
lower pH (sig), Higher APTT (sig), Higher ATIII level (NS),
Correction of ATIII deficiency (sig), Mobilization (sig) f,
Number of position changes (sig) f
VERY LOW b,j,c
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that subclavian placement should remain the last choice
of site.
Infection rates rise most per catheter day for femoral
and jugular sites [77, 79] thus we suggest that in patients
where CRRT is anticipated to extend beyond 7–10 days
a tunnelled semi-permanent device via an internal jugu-
lar vein could offer the optimal filter life with minimal
infection risk.
Femoral sites may also predispose to an increased risk
of deep venous thrombosis though this finding is not
universal [81, 82]. The clinical risk of lower limb deep
vein thrombosis however is greater than upper limb
thrombosis.
Variations in catheter design have been extensively de-
scribed [1–3, 83]. This meta-analysis does suggest a
trend toward some catheter designs being superior how-
ever to date studies have been small and at high risk of
confounding and bias. Future catheter technology ideally
should be subject to more rigorous comparisons.
Circuit factors
The evidence base for justifying decisions regarding op-
timal CRRT mode of therapy is weak though CVVHD-F
does appear to offer superior filter life to CVVH consist-
ently in all studies. Even this conclusion is complicated
by multiple interacting factors including anticoagulation
choice, blood flow determination, nursing expertise and
vascular access.
The literature remains unclear in regards to optimal
choice of haemofilter membrane despite several evolu-
tions of this technology. Recent advances such as hep-
arin bonded surfaces to minimise cytokine activation
and activation of clotting do not have a strong evidence
base to demonstrate superiority in regards to filter life
though as individual study authors point out, any effect
may be synergistic with choice of anticoagulation [43].
Advantages of improved biocompatibility may not be
evident in filter life but in overall patient tolerance with
an endotoxic shock model in dogs suggesting improved
haemodynamic function with polyacrylonitrile over poly-
sulfone [84] membranes.
Factors such as utilising larger surface area haemofil-
ters to gain longer filter life require more data to dem-
onstrate if any benefit exists from either a filter life, cost
or performance perspective. Larger area membranes in-
crease clearance of solutes and for the same flow rates
facilitate more rapid restoration of physiologic electro-
lytes however patient outcome studies are required to
determine if this translates to clinical improvement.
Conversely there seems little evidence to support saline
flushes of circuits used with or without anticoagulation
and theoretically this practice may expose the blood path
to increased risk of microbial contamination.
There is scope to further investigate optimal blood
flow rate in larger datasets or randomised studies while
controlling for consistency in anticoagulation and vascu-
lar access as this is a simple parameter to adjust that
affects both membrane performance and, our results
suggest, filter life. Such studies should also address alarm
frequency as blood flow increases as we hypothesise that
any benefit would reach a maximum after which the
frequency of access pressure alarms would increase.
Only two studies were found focussing on change
management and strategies for staff managing CRRT
Table 5 Summary of findings table (Continued)
Factors with a negative
association with filter life
Being male (NS), Mechanical Ventilation (sig) f, Increased
temperature (NS) f, Liver failure with bilirubin > 3 mg/dL
(NS) f, Presence of Sepsis (NS) f, Higher SOFA score (sig) f,
Higher LOD score (sig) f, Unit increase in ionized calcium
(sig), Higher platelet count (sig), RBC transfusion (sig) f,
Platelet transfusion (NS) f, FFP transfusion (NS) f,
PF4 antibodies f, Elevated fibrinogen (sig) f,
Prothrombin fragment (F1 + 2) elevation f
VERY LOW b,j,c
GRADE Working Group grades of evidence:
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a
possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aSignificant heterogeneity exists and potential for confounders
bTiming of catheters during admission has not been studied. Other factors such as choice of catheter length, insertion technique/operator experience at different
sites and catheter size at different sites may bias results
cHeterogeneity across small observational studies
dUnblinded (however unavoidable) however unlikely to affect results
eOne direct study, strong suggestion that the benefit of tunneled access could be due to catheter size, large RCT post hoc suggests larger size important
fSingle study, low numbers
gBefore - after studies with significant risk of other practice changes
hMixed composite of varying quality and study designs with no direct comparison between groups
iSome studies used composite interventions
jMostly small observational studies with high risk of bias
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despite this therapy consuming significant human re-
sources with frequent bag changes, alarms and poor filter
life predominating. Approach to alarms, catheter position-
ing, choice of blood flow and general trouble shooting
likely varies widely yet has been only touched upon spar-
ingly in filter life studies.
Patient factors
Patient factors associated with filter life are summarised
in Table 5 and in general result from a weak evidence
base. Many factors that positively influenced filter life
are biologically feasible though the trend in a single
study of mobilisation improving filter life requires
replication.
No studies reported subgroup analysis where indices
of body mass index (BMI) were assessed for an effect on
filter life. Similarly, no studies described the effects of
patient sedation and only one study described an inter-
action with ventilation despite both factors appearing at
the bedside to influence CRRT interruptions.
More work is required in the group with coagulation
disorders such as decreased anti-thrombin (heparin
resistance), PF4-heparin antibodies and elevated fibrino-
gen. ‘Clotty’ patients have long been recognised as detri-
mental to CRRT and though the recent expansion of
alternatives to heparin (particularly citrate anticoagula-
tion) have broadened therapeutic options these patients
still present a challenge frequently cycling through
different strategies empirically or unique un-trialled
interventions such as plasma exchange for frequent
circuit failure with hyperfibrinogenemia [85].
Limitations
Future data may clarify if effects such as increasing
temperature being negatively associated with filter life
remain significant. By not randomising for these out-
comes there is a significant risk of unquantified bias
explaining the effect or multicollinearity where the ob-
served effect is actually tracking another measured or
latent variable [22, 25, 86, 87]. For example, the trend
toward shorter filter life with elevated temperature may
track with the trend for sepsis and poor filter life. Given
that CRRT typically suppresses body temperature in all
but the hottest patients this is particularly possible.
Risk of type I error also exists with an example being
APTT where the effect size for a unit increase in APTT
though statistically significant appears small (and in some
studies in an unexpected direction). Higher APTT values
would biologically be expected to prolong extracorporeal
circuit life however it is an important variable that practi-
tioners of CRRT control or target toward fixed values thus
it is not a ‘free’ variable in the regression [86].
The overall quality of evidence from studies is low
with few randomised studies and none of significant size.
For many variables, effect sizes were extracted from sub-
analysis utilising either multiple regression or Cox pro-
portional hazards models and this poses limitations on
interpretation. For isolated statistically significant find-
ings from single sub-analysis there is a risk of the effect
resulting from pure chance i.e. a type II error – however
if an association is biologically plausible and is consistent
across several studies then it is a strength of meta-
analyses that it won’t be dismissed.
This systematic review highlighted the dearth of ran-
domised studies to guide practice and the overall low
quality of most studies. A significant risk of publication
bias exists given the 102 anti-coagulant comparison
studies in CRRT each of which would have had vascular
access, circuit and patient properties that was only
presented in sub-analyses of 10 studies – we deemed it
impractical to pursue this volume of unpublished data.
Given the limitations above the findings of this meta-
analysis should be considered as a summary of published
data and remain hypothesis generating.
The diversity of current practice and limited numbers
of large controlled trials significantly hamper interpret-
ation of findings. However, many effects that reached
significance are largely consistent with clinical experi-
ence and highlight where clinical decision making and
future studies should consider the existing data such as
around timing of transfusions, involvement of mobilisa-
tion and coagulation strategies in septic patients.
This review is useful in highlighting the weak under-
pinnings of current clinical practice in this area. Filter
life is an objective measurement that can readily be
followed within a unit as a quality control and under-
standing factors that influence variability will aide im-
provements of this index.
This review also highlighted some omissions in the
literature; though studies have looked at operator experi-
ence and ultrasound guided insertion in relation to
vascular access complications [88–90], filter life has not
been assessed as an outcome of ultrasound guided cath-
eter placement. Studies of alarm frequency by catheter
site and interactions with patient position need further
investigation. No studies reported on an interaction be-
tween catheter site and body habitus in regards to filter
life – we postulate that patients with centripetal obesity
may be more likely to receive jugular catheters and this
may interact with filter life. No studies looked at
catheter care and locking in relation to filter life.
Conclusion
Despite the improvements in device technology and
usability, filter life remains highly variable across pub-
lished literature. This is somewhat unsurprising given
the myriad of interacting patient, vascular access site
and type and circuit factors. Perhaps more surprising is
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the absence of strong guiding evidence outside of anti-
coagulation strategies after over 20 years of therapy
delivery. Significant ongoing data collection is required
to elucidate the optimal technological and management
strategies to enhance current delivery of care to provide
optimal performance with minimal disruption at the
least cost.
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